Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Astellas’ Xtandi on 2nd Drug List Up for IRA Price Negotiations
The US government has announced a total of 15 drugs up for the second round of Medicare price negotiations under the Inflation Reduction Act (IRA), with Astellas Pharma’s flagship cancer therapy Xtandi (enzalutamide) among them. The US Department of Health…
To read the full story
Related Article
- Entyvio, Rexulti, and Lenvima among 15 More Drugs Picked for IRA Price Talks
January 29, 2026
- US Unveils Up to 85% Price Cuts for IRA Round-2; Astellas’ Xtandi on the List
November 27, 2025
- Astellas Drops IRA Lawsuit after Xtandi Avoids 1st Drug List
September 8, 2023
- First 10 Drugs Named for Medicare Price Negotiations, None from Japan Firms
August 30, 2023
- Astellas Becomes 1st Japan Pharma to Sue US Govt over IRA
July 19, 2023
REGULATORY
- Japan Begins Review of Domestic CGT Seeds with Limited Market Potential
June 30, 2026
- Govt Panel Urges 2027 Bill to Expand Secondary Use of Health Data
June 30, 2026
- Japan Panel OKs Carvykti’s Earlier Use in Multiple Myeloma
June 30, 2026
- Govt to Explore Greater Rewards for Innovative Drugs in Honebuto
June 29, 2026
- MHLW Starts Technical Review of OTC-Like Drug Charge Exemptions
June 29, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…